Corrigendum to "Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression" [Gynecol. Oncol. 104 (2007) 352-361] (DOI:10.1016/j.ygyno.2006.08.054);Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 352-361

  Ramdass, Bharathi ^a   Maliekal, Tessy T ^a   Lakshmi, S ^b   Rehman, Michael ^a   Rema, P ^b   Nair, Pradip ^a   Mukherjee, Geetashree ^c   Reddy, B K M ^c   Krishna, Sudhir ^a   Radhakrishna Pillai, M ^d  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^d RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Cervical cancer; Human papillomavirus; NF kappa B; Notch1

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 9; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN P50; TRANSCRIPTION FACTOR HES 1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; UTERINE CERVIX CANCER; XENOGRAFT;

EID: 33846392694     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.020     Document Type: Erratum

References (46)

1. zur Hausen H. Genital papillomavirus infections. Prog. Med. Virol. 32 (1985) 15-21
2. Zagouras P., Stifani S., Blaumueller C.M., Carcangiu M.L., and Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 6414-6418
3. Veeraraghavalu K., Pett M., Kumar R.V., Nair P., Rangarajan A., Stanley M.A., et al. Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J. Virol. 78 (2004) 8687-8700
4. Daniel B., Mukherjee G., Seshadri L., Vallikad E., and Krishna S. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. J. Gen. Virol. 76 Pt. 10 (1995) 2589-2593
5. Artavanis-Tsakonas S., Rand M.D., and Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 284 (1999) 770-776
6. Lathion S., Schaper J., Beard P., and Raj K. Notch1 can contribute to viral-induced transformation of primary human keratinocytes. Cancer Res. 63 (2003) 8687-8894
7. Nair P., Somasundaram K., and Krishna S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J. Virol. 77 (2003) 7106-7112
8. Rangarajan A., Syal R., Selvarajah S., Chakrabarti O., Sarin A., and Krishna S. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology 286 (2001) 23-30
9. Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu Y., Androphy E.J., Stanley M.A., et al. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J. Virol. 78 (2004) 5934-5945
10. Subramanyam D., and Krishna S. c-Myc substitutes for Notch1-CBF1 functions in cooperative transformation with papillomavirus oncogenes. Virology 347 (2006) 191-198
11. Veeraraghavalu K., Subbaiah V.K., Srivastava S., Chakrabarti O., Syal R., and Krishna S. Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J. Virol. 79 (2005) 7889-7898
12. Talora C., Sgroi D.C., Crum C.P., and Dotto G.P. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 16 (2002) 2252-2263
13. Weijzen S., Zlobin A., Braid M., Miele L., and Kast W.M. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell. Physiol. 194 (2003) 356-362
14. Prusty B.K., Husain S.A., and Das B.C. Constitutive activation of nuclear factor-kB: preferential homodimerization of p50 subunits in cervical carcinoma. Front Biosci. 10 (2005) 1510-1519
15. Nair A., Venkatraman M., Maliekal T.T., Nair B., and Karunagaran D. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22 (2003) 50-58
16. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev., Cancer 2 (2002) 301-310
17. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
18. Baldwin Jr. A.S., Azizkhan J.C., Jensen D.E., Beg A.A., and Coodly L.R. Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol. Cell. Biol. 11 (1991) 4943-4951
19. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev. 18 (2004) 2195-2224
20. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol. 64 (2002) 883-888
21. Guan E., Wang J., Laborda J., Norcross M., Baeuerle P.A., and Hoffman T. T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J. Exp. Med. 183 (1996) 2025-2032
22. Bellavia D., Campese A.F., Alesse E., Vacca A., Felli M.P., Balestri A., et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 19 (2000) 3337-3348
23. Shin H.M., Minter L.M., Cho O.H., Gottipati S., Fauq A.H., Golde T.E., et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J. 25 (2006) 129-138
24. Wang J., Shelly L., Miele L., Boykins R., Norcross M.A., and Guan E. Human Notch-1 inhibits NF-kappa B activity in the nucleus through a direct interaction involving a novel domain. J. Immunol. 167 (2001) 289-295
25. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., and Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66 (2006) 2778-2784
26. Nair P., Nair K.M., Jayaprakash P.G., and Pillai M.R. Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. Pathol. Oncol. Res. 5 (1999) 95-103
27. Nickoloff B.J., Osborne B.A., and Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22 (2003) 6598-6608
28. Vasko V., Saji M., Hardy E., Kruhlak M., Larin A., Savchenko V., et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41 (2004) 161-170
29. Perez-Tenorio G., and Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86 (2002) 540-545
30. Kreisberg J.I., Malik S.N., Prihoda T.J., Bedolla R.G., Troyer D.A., Kreisberg S., et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 64 (2004) 5232-5236
31. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S.M., Dunne B., Lyon A., et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 207 (2005) 139-146
32. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., and Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75 (2001) 4283-4296
33. Hou M.F., Lin S.B., Yuan S.S., Tsai S.M., Wu S.H., Ou-Yang F., et al. The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. Clin. Chim. Acta 334 (2003) 137-144
34. Shukla S., MacLennan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I., et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6 (2004) 390-400
35. Yu H.G., Yu L.L., Yang Y., Luo H.S., Yu J.P., Meier J.J., et al. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 65 (2003) 37-45
36. Fu M., Wang C., Li Z., Sakamaki T., and Pestell R.G. Minireview: CyclinD1: normal and abnormal functions. Endocrinology 145 (2004) 5439-5447
37. Brychtova S., Brychta T., Kotrsova L., Pilka R., Tichy M., Ticha V., et al. Expression of Bcl-2 in dysplastic and neoplastic cervical lesions in relation to cell proliferation and HPV infection. Neoplasma 47 (2000) 143-147
38. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
39. Espinosa L., Ingles-Esteve J., Robert-Moreno A., and Bigas A. IkappaBalpha and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between Notch and NFkappaB pathways. Mol. Biol. Cell 14 (2003) 491-502
40. Ryan K.M., Ernst M.K., Rice N.R., and Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404 (2000) 892-897
41. Brenna S.M., Zeferino L.C., Pinto G.A., Souza R.A., Andrade L.A., Vassalo J., et al. P53 expression as a predictor of recurrence in cervical squamous cell carcinoma. Int. J. Gynecol. Cancer 12 (2002) 299-303
42. Grace V.M., Shalini J.V., lekha T.T., Devaraj S.N., and Devaraj H. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 91 (2003) 51-58
43. Kumar A., Zhao Y., Meng G., Zeng M., Srinivasan S., Delmolino L.M., et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 22 (2002) 5801-5812
44. Bamberger A.M., Milde-Langosch K., Rossing E., Goemann C., and Loning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J. Cancer Res. Clin. Oncol. 127 (2001) 545-550
45. Prusty B.K., and Das B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 113 (2005) 951-960
46. Cheung T.H., Leung J.O., Chung T.K., Lam S.K., To K.F., and Wong Y.F. c-fos overexpression is associated with the pathoneogenesis of invasive cervical cancer. Gynecol. Obstet. Invest. 43 (1997) 200-203